AUS
NZ
UK
CA
USA
IND
Highlights
- Invex Therapeutics shares increased by 12% in a week
- A significant decrease of 88% over three years
- Total Shareholder Return (TSR) outperforms share price drop
Invex Therapeutics Ltd (ASX:IXC) has witnessed a 12% rise in its share price over the last week. This is a positive turn considering the 88% decline experienced over the past three years. Such improvement could indicate a potential shift in the company’s trajectory.
Investment in companies like Invex, which have limited revenue, often carry certain risks. In the past year, Invex's revenue stood at around AU$1,212,256, which suggests that current revenues have not yet solidified its business model. As a result, investors may be focusing more on potential future prospects rather than the present financial metrics.
Despite these concerns, Invex's strong cash position, with AU$5.3 million surpassing all liabilities at the last report in December 2024, provides a level of stability. Over the past three years, investor enthusiasm drove the stock prices down by an annual average of 23%, reflecting possibly overestimated past expectations.
The company’s TSR of -53%, including the inferred benefits from discounted capital raisings or potential spin-offs, indicates an added value to shareholders compared to the direct share price change of -88%. Such figures highlight that the company has undertaken efforts that translated into some shareholder returns despite not issuing dividends.
Recent performances have been less than favorable with shares down 25% over the past year, while the market grew by 4.0%. It's essential to approach with caution, aligning with the thought from Baron Rothschild about the opportune moments to invest. However, ensuring the business quality remains paramount before any leaps of faith.
Although historical share price trends serve as a proxy for business performance, it's crucial to consider additional information. Prospective stakeholders should stay informed about potential warnings regarding Invex Therapeutics and consider exploring other investment analyses.
